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Summary 
Cathepsin B (CTSB) and cathepsin L (CTSL) are two widely expressed cysteine 
proteases thought to predominantly reside within lysosomes. Functional analysis of 
CTSL in humans is complicated by the existence of two CTSL-like homologues 
(CTSL and CTSL2), in contrast to mice which contain only one CTSL enzyme. Thus 
transgenic expression of human CTSL in CTSL deficient mice provides an 
opportunity to study the in vivo functions of this human protease without interference 
by its highly related homologue. While mice with single gene deficiencies for murine 
CTSB or CTSL survive without apparent neuromuscular impairment, murine 
CTSB/CTSL double deficient mice display degeneration of cerebellar Purkinje cells 
and neurons of the cerebral cortex, resulting in severe hypotrophy, motility defects, 
and lethality during their third to fourth week of life. Here we show that expression of 
human CTSL through a genomic transgene results in widespread expression of 
human CTSL in the mouse which is capable of rescuing the lethality found in 
CTSB/CTSL double-deficient animals. Human CTSL is expressed in the brain of 
these compound mutants predominantly in neurons of the cerebral cortex and in 
Purkinje cells of the cerebellum, where it appears to prevent neuronal cell death.  
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Introduction 
Cathepsins are proteolytic enzymes with a principal subcellular localization in the 
endosomal/lysosomal compartment. The largest family of cathepsins comprises the 
papain-like cysteine proteases with 11 human enzymes (Turk et al., 2001). As a 
result of a gene duplication, the human genome encodes for two cathepsin L-like 
proteases, namely the “classic” human cathepsin L (CTSL), which is produced by a 
wide range of tissue and cell types, as well as cathepsin L2 (CTSL2; alternatively 
termed cathepsin V) with a more restricted expression pattern (Brömme and Kaleta, 
2002). In contrast, the mouse genome contains only one CTSL gene, which is 
ubiquitously expressed (Brömme and Kaleta, 2002). All three enzymes, murine 
CTSL, human CTSL and human CTSL2, are highly homologous with about 75% 
amino acid identity, which complicates the assignment of biological functions to the 
human enzymes (Brömme and Kaleta, 2002; Hagemann et al., 2004). Thus we 
sought to study the expression of human CTSL in CTSL-deficient mice to assess in 
vivo functions of the human protease without interference of its highly related 
homologue. 
 
CTSL-deficient mice develop dilated cardiomyopathy (Stypmann et al., 2002) as well 
as epidermal hyperproliferation, retardation of hair follicle morphogenesis and 
alterations of the hair cycle (Reinheckel et al., 2005; Roth et al., 2000; Tobin et al., 
2002). Murine CTSL is critical for MHC class II mediated antigen presentation in 
cortical epithelial cells of the thymus (Honey et al., 2002; Nakagawa et al., 1998). 
Furthermore, CTSL is involved in generating hypophyseal neuropeptides (i.e. 
enkephalin) and, in combination with cathepsin K and B, is responsible for 
solubilization of thyroglobulin and the release of thyroid hormones (Friedrichs et al., 
2003; Yasothornsrikul et al., 2003). Recently, the critical role of CTSL for endothelial 
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progenitor cell–induced neovascularization in a hind limb ischemia model was 
demonstrated (Urbich et al., 2005). However, CTSL knockout mice are fertile, 
reproduce normally and do not develop a pathological neuromuscular phenotype. In 
contrast to CTSL deficient animals, CTSB knockout mice do not show any obvious 
spontaneous phenotype (Reinheckel et al., 2001). Nevertheless, under environment 
stress experiments CTSB proved to have a major role in pathological trypsinogen 
activation in the early course of experimental pancreatitis (Halangk et al., 2000), as 
well as to contribute significantly to TNF-α induced hepatocyte apoptosis (Guicciardi 
et al., 2000). In contrast to the single gene mutations, CTSB/CTSL double mutant 
mice exhibit a severely impaired life expectancy. While mice with CTSB/CTSL double 
deficiency are born at the expected Mendelian ratios, they die during their third to 
fourth week of life (Felbor et al., 2002). Felbor et al proposed that this lethality is most 
likely due to degeneration of cerebellar Purkinje cells and neurons of the cerebral 
cortex, which results in severe hypotrophy, motility defects, and ultimately death  
(Felbor et al., 2002). 
The aim of the present study was to express human CTSL from a genomic transgene 
and to compare postnatal development, brain histology and cathepsin L expression 
of the triple mutant Tg(hCTSL);Ctsb-/-Ctsl-/- with Ctsb-/-Ctsl-/- double knockouts and 
wild-type controls.  
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Results  
Expression of transgenic human CTSL. 
We previously generated a human CTSL transgenic through the use of a publicly 
available Bacterial Artificial Chromosome clone (CTD-2062O4) (Houseweart et al., 
2003). In order to assess the expression of the transgene, we examined human 
CTSL mRNA and protein levels as well as enzymatic activity in a panel of mouse 
tissues (Figure 1). Amplification of a specific 152 bp fragment of human CTSL cDNA 
was observed after RT-PCR of RNAs isolated from the human cell line HEK293 or 
from liver of transgenic Tg(hCTSL) mice, while material from nontransgenic mice did 
not show a specific RT-PCR product (Figure 1A). By using these primers in 
quantitative “real time” RT-PCR, we determined the relative level of the hCTSL 
transcript in several tissues from these transgenic mice (Figure 1B). Liver, followed 
by kidney, showed the highest level of human CTSL mRNA expression, while heart, 
skeletal muscle and brain displayed lower expression. This expression pattern was 
largely confirmed by Western blotting, although kidney revealed somewhat higher 
abundance of human CTSL than liver, suggesting a difference in their post-
transcriptional processing (Figure 1C). Interestingly, pro-CTSL was almost 
undetectable in brain samples indicating that the protease is predominantly activated 
in the central nervous system, in contrast to other tissues???. Furthermore, we 
compared the degradation of the common CTSL substrate z-Phe-Arg-AMC (in 
presence of the specific CTSB inhibitor CA074) in samples of wild-type and triple 
mutant Tg(hCTSL);Ctsb-/-Ctsl-/- mice, which are deficient for the murine proteases 
CTSB and CTSL (Figure 1D). Comparison of wild-type and transgenic mice revealed 
that the degradation of the fluorogenic peptide was widely different with livers and 
kidneys of transgenic mice showing 4-fold and 10-fold increases of z-Phe-Arg-AMC 
cleavage as compared to wild-type mice. In contrast, CTSL activities in cerebral 
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cortex and cerebellum were similar to control animals (Figure 1D). In summary these 
data indicate that the genomic transgene exerts control on tissue specific expression 
quantities of the human CTSL in the mouse, and a proteolytic active human CTSL is 
produced. However, these transgenic mice appear outwardly normal with no 
apparent effects on fertility, reproduction or viability. In order to determine if the 
human transgene could complement the mouse CTSB/CTSL deficient phenotypes, 
we crossed them consecutively with CTSB and CTSL knockout mice in order to 
obtain the triple mutant Tg(hCTSL);Ctsb-/-Ctsl-/-. 
 
The lethal phenotype of CTSB/CTSL double deficient mice is rescued by the 
expression of human CTSL. 
In contrast to the study of Felbor et al, which used CTSB/CTSL double deficient mice 
of a mixed C57BL/6 x 129/Sv genetic background (Felbor et al., 2002), the 
CTSB/CTSL double deficient mice used in the present study were backcrossed for at 
least 6 generations to the FVB/n background resulting in a more uniform genetic 
background since their original generation (Halangk et al., 2000, Roth et al., 2000). 
At the age of 16 days Ctsb-/-Ctsl-/- as well as Tg(hCTSL);Ctsb-/-Ctsl-/- 
exhibitedretarded fur growth (Figure 2A), while body weight was similar to the Ctsb-/-
Ctsl+/- control mice that showed a weight gain identical to FVB/n wild-type mice 
(Figure 2B). However, CTSB/CTSL double deficient mice developed severe 
hypotrophy and neuromuscular dysfunction, characterized by ataxia, mild rear limb 
spasticity, and physical inactivity, during the next 7-10 days of life.  This phenotype 
twas completely rescued by expression of human CTSL in Tg(hCTSL);Ctsb-/-Ctsl-/- 
mice (Figure 2A, B). Body weight of Ctsb-/-Ctsl-/- males and females ranged between 
3-5 g in the forth week of life, and animals were sacrificed at this stage. In contrast, 
the males and females of the triple mutant Tg(hCTSL);Ctsb-/-Ctsl-/- showed a slightly 
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retarded weight gain during the third to fifth week of life, however, at 35 days body 
weights reached the control group and mice were viable for observation periods of up 
to one year (Figure 2B). Interestingly, Tg(hCTSL);Ctsb-/-Ctsl-/- showed the periodic 
hair loss that is characteristic for mice with single deficiency for the murine CTSL 
(Figure 2A).  
Cell type specific expression of human CTSL in the central nervous system is 
associated with prevention of Purkinje cell degeneration. 
Purkinje cells possess the only efferent neurites of the cerebellar cortex and control 
muscle movements by their inhibitory action on cerebellar nuclei. Strikingly, 
CTSB/CTSL double deficient mice revealed a specific loss of Purkinje cells coinciding 
with neuromuscular impairment, while cerebella of mice with single deficiencies for 
CTSB or CTSL showed a normal Purkinje cell layer (Figure 3 A-E). The other layers 
of the cerebellar cortex, namely the molecular and granular cell layers, did not exhibit 
histomorphological alterations. Strikingly, the triple mutant Tg(hCTSL);Ctsb-/-Ctsl-/- 
showed a complete rescue of Purkinje cells supporting a highly conserved function of 
CTSL activity for maintenance of this cell layer (Figure 3E).  
In order to localize CTSL expression in mouse cerebral and cerebellar cortex, 
immunohistochemistry for murine CTSL and for transgenic human CTSL was 
performed (Figures 4 and 5). In the cerebral cortex murine CTSL is highly expressed 
in the pyramidal cell neurons (Figure 4A, B). This cerebral expression pattern is 
clearly recapitulated by the expression of human CTSL in Tg(hCTSL);Ctsb-/-Ctsl-/- 
mice (Figure 5 A,B). However, histopathological lesions have not been detected in 
the cerebral cortex of CTSB/CTSL double deficient FVB/n congenic mice (Figure 5 C, 
D). Murine CTSL is highly abundant in cerebellar Purkinje cells with a staining 
intensity clearly exceeding the decoration of the other cell layers (Figure 4 D). 
Strikingly, human CTSL is strongly expressed by the cerebellar Purkinje cell layer of 
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Tg(hCTSL);Ctsb-/-Ctsl-/- mice (Figure 5E, F). Thus, both the mouse CTSL and human 
transgenic human CTSL express in similar patterns in the brain. Furthermore, 
transgene expression in Purkinje cells is associated with the prevention of Purkinje 
cell death supporting the intrinsic need for CTSL in these specific cells of the 
cerebellum.  
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Discussion 
Because of their principal endosomal/lysosomal localizations and redundant 
substrate specificities, cysteine cathepsins are thought to cooperate in terminal 
degradation of proteins upon delivery to lysosomes by endocytosis or autophagy 
(Ciechanover, 2005). However, individual cell types show a differential requirement 
for the presence of various cysteine cathepsins. Cerebellar Purkinje cells are highly 
susceptible to the loss of cathepsins B and L. Although present after birth (Felbor et 
al., 2002), these cells degenerate during the first weeks of life. In contrast to Felbor et 
al. cerebral atrophy and astrogliosis were not observed in our analysis of Ctsb-/-Ctsl-/- 
mice (Felbor et al., 2002). This might be explained by differences in the mouse strain, 
congenic FVB (this study) versus mixed C57BL/6 x 129/Sv, or since Felbor et al. 
nursed some Ctsb-/-Ctsl-/- mice up to an age of 50 days at which marked cerebral 
atrophy was found (Felbor et al., 2002). Thus it appears that degeneration of Purkinje 
cells represents an early pathogenic event in the brain of CTSB/CTSL double 
deficient mice while cerebral atrophy occurs later in pathogenesis. Since Purkinje 
cells are critical for the refinement of movement, the loss of these cells is likely to 
cause the neuromuscular phenotype of CTSB/CTSL double knockout mice. In 
extension of the study of Felbor et al. (Felbor et al., 2002), we report an expression 
pattern of murine CTSL in wild-type brain that corresponds to the cell types that are 
highly susceptible to the loss of cathepsins, namely the cerebellar Purkinje cells and 
the neurons of the cerebral pyramidal cell layer. The brain phenotype of CTSB/CTSL 
double deficient mice provides a clear example for the functional redundancy among 
lysosomal cathepsins, since mice with single deficiencies of CTSB or CTSL do not 
show neuronal loss or neuromuscular symptoms. This is further supported by the 
finding of a rescue of Purkinje cell loss by transgenic expression of human CTSL in 
CTSB/CTSL double deficient mice. Consistent with this observation, in the brain the 
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human CTSL genomic transgene shows a similar expression pattern  andCTSL 
activity as endogenous mouse CTSL. In contrast, in other tissues (i.e. kidney and 
liver) the transgene construct results in a 4-10 fold excess of CTSL activity as 
compared to wild-type mice. However, this over-expression did not result in a gross 
phenotype. Interestingly, not all phenotypes of Ctsb-/-Ctsl-/- mice are rescued by the 
human CTSL transgene. The early postnatal phenotype of mice with CTSB/CTSL 
double deficiency is characterized by a delay of hair development, which is also a 
hallmark of mice with single deficiency of CTSL (Roth et al., 2000; Tobin et al., 2002). 
As shown in figure 2, Tg(hCTSL);Ctsb-/-Ctsl-/- mice still show this characteristic 
pattern of hair loss. It has been shown that this skin phenotype of CTSL deficient 
mice depends on CTSL activity in keratinocytes of hair follicles and of the basal 
epidermal layer (Hagemann et al., 2004; Reinheckel et al., 2005). The question of 
whether active human CTSL is expressed in keratinocytes of Tg(hCTSL) mice or if 
human CTSL is not capable of executing the murine CTSL functions in these cell 
types is currently under investigation. 
Over the past years evidence of cell type specific functions of lysosomal cysteine 
cathepsins in the brain has been accumulating. As discussed above, cerebellar 
Purkinje cells are affected by the combined loss of cathepsins B and L. Interestingly, 
mutations of the cysteine protease inhibitor cystatin B (stefin B) result in apoptosis of 
cerebellar granule cells and cause progressive ataxia and a progressive myoclonus 
epilepsy (EPM1; Unverricht-Lundborg disease) in humans and in a mouse model 
(Lieuallen et al., 2001; Pennacchio et al., 1996; Pennacchio et al., 1998). Breeding of 
cathepsin B deficient mice to cystatin B knockout mice could ameliorate the 
neurological phenotype (Houseweart et al., 2003). Thus, an excess of cysteine 
cathepsin activity, i.e. CTSB activity, in the cerebellum contributes to the 
neurodegeneration of granule cells, while the loss of cysteine cathepsins results in 
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degeneration of the neighbouring Purkinje cells. Deletion of another cysteine 
cathepsin inhibitor, cystatin C, promotes neuronal injury after focal brain ischemia but 
is protective after global ischemia, indicating a fine balance of cysteine cathepsins 
and their inhibitors in pathological processes of the brain (Olsson et al., 2004). 
Furthermore, CTSB has been implicated in the generation of β-amyloid in the 
regulated secretory pathway of neuronal chromaffin cells and, therefore, in 
Alzheimers neurodegenerative disease (Hook et al., 2005). CTSL has been shown to 
be involved in the processing of hypophyseal neuropeptides, i.e. enkephalin, from 
their precursor molecule (Hook et al., 2004; Yasothornsrikul et al., 2003).  
 
In summary, present evidence indicates cell type specific functions of cysteine 
cathepsins in various physiological and pathological processes of the central nervous 
system. The study of transgene expressed human cathepsins in absence of their 
murine orthologues provides a valuable tool for investigation of the in vivo functions 
of the human enzymes in the brain. Our present results correlate the expression of 
human CTSL to the prevention of Purkinje cell degeneration and to the rescue of the 
severe neuromuscular phenotype of mice with double deficiency for CTSB and 
CTSL.  
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Materials and Methods 
Animals 
Generation of Tg(hCTSL) mice has been described by Houseweart et al (Houseweart 
et al., 2003). Briefly, a human CTSL BAC clone (CTD-2062O4) was identified by 
sequence homology search, and BAC DNA was micro-injected into fertilized FVB 
blastocysts using standard procedures. Cathepsin B and cathepsin L deficient mice 
(Halangk et al., 2000, Roth et al., 2000) were backcrossed for at least 6 generations 
on FVB/n background. Transgenic Tg(hCTSL) mice were crossed with the congenic 
cathepsin L deficient mouse line to generate Tg(hCTSL);Ctsl-/- mice. Ctsb-/-Ctsl+/- 
were crossed with Tg(hCTSL);Ctsl-/- to obtain mice with the genotype 
Tg(hCTSL);Ctsb-/-Ctsl-/-. 
RT-PCR and quantitative real time PCR  
Total RNA from the human cell line HEK293 and murine tissues was prepared using 
the “RNeasy Mini kit” (Qiagen, Hilden, Germany). Reverse transcription for the 
generation of cDNA from total RNA was performed by using a first strand cDNA 
synthesis kit (Invitrogen, Karlsruhe, Germany). For expression analysis of human 
cathepsin L and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), PCR 
amplification was performed using equivalent amounts of the intercalating SYBR-
green dye, cDNA/RNA, Taq-polymerase, and specific primers (hCTSL: 
5´-gaatcctacactcatccttgctgcc-3´ and 5´-acactgctctcctccactcttcttc-3´; GAPDH: 
5´-tgcaccaccaactgctta-3´ and 5´-gatgcagggatgatgttc-3´) under the following 
conditions: 1 cycle for 1 minute at 72°C, 50 cycles (94°C for 15 seconds, 60°C for 30 
seconds, 72°C for 30 seconds) and 1 cycle at 72°C for 7 minutes in the MyiQTM 
single-color real-time PCR detection system (BioRad, München, Germany). The 
resulting PCR products were visualized by ethidium bromide staining after separation 
on 1.5% (w/v) agarose gels. 
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Detection of human cathepsin L by Western blotting 
Murine tissues (100 mg) were homogenized in 500 µl homogenization buffer (10 mM 
Tris, 128 mM NaCl, 1 mM EDTA, 1 mM Pefablock, 100 µM Pepsatin A, 10 µM 
Leupeptin, pH 7.5) using an Ultrathurrax followed by Dounce homogenization and 
centrifuged at 1000 g for 15 min. Postnuclear supernatants (75 µg protein) were 
applied to 15% SDS-PAGE under reducing conditions and subsequently blotted to a 
PVDF membrane. Goat anti-human CTSL antibody (R&D Systems, Wiesbaden, 
Germany) at a 1:500 dilution and mouse anti-mouse actin antibody (ICN, 
Biochemicals, Aurora, OH) at 1:5000 dilution were used. The binding of secondary 
antibody anti-goat IgG-POD (Sigma, Saint Louis, USA) and anti-mouse IgG-POD 
(Calbiochem) at 1:5000 dilution was detected by the SuperSignalTM 
Chemiluminescent Substrate (Pierce, Rockford, IL). 
Detection of CTSL enzyme activity 
Fresh tissues (100 mg) were homogenized in 500 µl NaAc-Buffer (200 mM 
Sodiumacetate, 1 mM EDTA, 0,05% Brij) using an Ultrathurrax followed by Dounce 
homogenization and centrifuged at 1000 g for 15 min. CTSL proteolytic activity was 
determined by degradation of the fluoropeptide z-Phe-Arg-4-methyl-coumarin-7-
amide (20 µM; Bachem) in the presence of the CTSB-specific inhibitor CA074 (1.5 
µM; Bachem) at pH 5.5. The release of 7-amino-4-methyl-coumarin was continuously 
monitored for 45 minutes by spectrofluorometry at excitation and emission 
wavelengths of 360 nm and 460 nm, respectively. 
Histology and Immunohistochemistry 
For histological assessment sagital brain sections of 5 µm thickness were 
deparaffinized in xylene, hydrated in graded ethanol solutions and stained with 
hematoxylin/eosin. Goat anti-mouse CTSL antibody (R&D Systems, Wiesbaden, 
Germany) at 1:500 dilution and goat anti-human CTSL antibody (R&D Systems, 
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Wiesbaden, Germany) at 1:50 dilution were used for the detection of murine and 
human CTSL, respectively. Peroxidase-based detection of the primary antibodies 
was performed according to the instructions of the “Vectastain Elite ABC Kit” (Vector 
Laboratories, Burlinghame, CA). Microscopy was performed with an Axioplan 
microscope (Zeiss, Stuttgart, Germany) and digital images were obtained with an 
Axiocam camera (Zeiss, Stuttgart, Germany). 
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Figure legends 
Fig.1. Expression of human CTSL in the transgenic Tg(hCTSL) mouse line. (A) 
RT-PCR for detection of hCTSL and GAPDH mRNA in the human cell line HEK293 
(lane 1-2) and liver of wildtype (lane 3-4) and Tg(hCTSL);Ctsl-/- mice (lane 5-6)+RT: 
cDNA samples with reverse transcription; -RT: total RNA without reverse 
transcription; M: 100 bp ladder. (B) Quantitative real time PCR for quantification of 
transgenic human CTSL and GAPDH mRNA in liver, kidney, heart, brain and skeletal 
muscle of Tg(hCTSL);Ctsl-/- mice (n=3). (C) Western blot for detection of transgenic 
human CTSL in liver of wildtype (Ctsl+/+), cathepsin L deficient mice (Ctsl-/-) and in 
liver, kidney, heart, brain and skeletal muscle of Tg(hCTSL);Ctsl-/- mice. (D) 
Proteolytic activity of murine CTSL and transgenic human CTSL in liver, kidney, 
cerebral cortex and cerebellum of wildtype (Ctsb+/+Ctsl+/+) and Tg(hCTSL);Ctsb-/-Ctsl-
/- mice (n=3). Data in graphs are expressed as means ± s.e.m. 
 
Fig.2. Postnatal development of CTSB/CTSL double deficient mice. (A) Littermates 
were photographed 16 days, 26 days and 43 days after birth. Control mice (Ctsb-/-
Ctsl+/-; triangle), CTSB/CTSL double deficient mice (Ctsb-/-Ctsl-/-; star), and 
Tg(hCTSL);Ctsb-/-Ctsl-/- (arrow). (B) Weight gain of Tg(hCTSL);Ctsb-/-Ctsl-/- and Ctsb-/-
Ctsl-/- in comparison to Ctsb-/-Ctsl+/- control mice. Body weight was measured from 
day 15 to day 48 after birth. Ctsb-/-Ctsl-/- were sacrificed on day 26 after birth at the 
latest. Data in graphs are expressed as means ± s.e.m. 
 
Fig.3. Loss of Purkinje cells in CTSB/CTSL double deficient mice and complete 
rescue of the Purkinje cells in Tg(hCTSL);Ctsb-/-Ctsl-/-. H&E stained sagital sections 
of the cerebellar cortex of wildtype (Ctsb+/+Ctsl+/+; A), CTSB single deficient mice 
(Ctsb-/-Ctsl+/+; B), CTSL single deficient mice (Ctsb+/+Ctsl-/-; C), CTSB/CTSL double 
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deficient mice (Ctsb-/-Ctsl-/-; D) and Tg(hCTSL);Ctsb-/-Ctsl-/- mice (E). MC: molecular 
cell layer; PC: Purkinje cell layer; GC: granular cell layer. 
 
Fig.4. Expression of CTSL in the mouse brain. Immunohistochemical detection of 
murine CTSL in the cerebral (A-C) and cerebellar cortex (D-E) of wildtype (Ctsl+/+) (A-
B; D) and CTSL single deficient mice (Ctsl-/-) (C; E). CTSL is highly abundant in the 
pyramidal cell neurons of the inner and outer pyramidal cell layer of the cerebral 
cortex (A-B) and in the cerebellar Purkinje cell layer (D) OPC: outer pyramidal cell 
layer; IPC: inner pyramidal cell layer; MC: molecular cell layer; PC: Purkinje cell 
layer; GC: granular cell layer. 
 
Fig.5. Recapitulation of the CTSL expression pattern by the transgene within the 
mouse brain. Immunohistochemical detection of human CTSL in the cerebral (A-D) 
and cerebellar cortex (E-H) of Tg(hCTSL);Ctsb-/-Ctsl-/- (Tg(hCTSL);dKO, A-B; E-F) 
and Ctsb-/-Ctsl-/- (C-D; G-H). The transgenic human CTSL is highly abundant in the 
the pyramidal cell neurons of the inner and outer pyramidal cell layer of the cerebral 
cortex (A-B) and in the cerebellar Purkinje cells (E-F). OPC: outer pyramidal cell 
layer; IPC: inner pyramidal cell layer; MC: molecular cell layer; PC: Purkinje cell 
layer; GC: granular cell layer. 
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